Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kulynych-Miskiv (Galych, Ukraine). Tiotropium bromide: Efficacy and safety in complex treatment of COPD. 1797

Member's Comments

No comment yet.

Related content which might interest you: Twice-daily aclidinium bromide in COPD patients: Efficacy and safety results from ACCORD COPD I Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Doxofylline: Efficacy and safety in complex treatment of COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Efficacy and safety of extrafine glycopyrronium bromide pMDI (CHF 5259) in COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007 Sleep architecture in COPD patients during salmeterol versus tiotropium bromide treatment Source: Eur Respir J 2006; 28: Suppl. 50, 199s Year: 2006 Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Long-term efficacy of twice-daily aclidinium bromide in COPD patients: A one-year study Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Efficacy and safety of extrafine glycopyrronium bromide (GB) in uncontrolled asthmatic patients Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 ACCORD COPD I: Safety and tolerability of twice daily aclidinium bromide in COPD patients Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 Sleep architecture in COPD patients during salmeterol versus ipratropium bromide treatment Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004 Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012 Cost effectiveness of umeclidinium bromide 62.5µg plus ICS/LABA versus ICS/LABA in COPD Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 The ATTAIN study: Safety and tolerability of aclidinium bromide in chronic obstructive pulmonary disease Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 The efficacy of long-acting anticholinergic agent, tiotropium bromide on dynamic hyperinflation in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006